Key facts
- Viome Life Sciences’s last known valuation is $415.4M.
- It has raised $235.4M across 2 recorded rounds; the latest was Early Stage VC ($25.4M) in Aug 2024.
- Notable investors include Khosla Ventures, Marc Benioff, Eastward Capital Partners, BOLD Capital Partners, SquareOne Capital — 20 tracked in total.
- Viome Life Sciences has filed 2 Form Ds with the SEC since 2022, most recently Aug 2024 ($25.4M sold to 44 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Viome Life Sciences
Funding rounds
2 roundsAbout Viome Life Sciences
Operator of a biotechnology and healthcare company intended to prevent and reverse chronic diseases. The company digitizes the human body and its microbiomes on a molecular level using at-home clinical-grade tests, analyzed through proprietary ribonucleic acid sequencing technology, and decodes precise health insights and biomarkers of various chronic diseases using artificial intelligence and systems biology expertise, enabling healthcare providers to give personalized nutrition recommendations and precision supplements to their patients.
- Sector
- Healthcare
- HQ
- Bellevue, WA, United States
- Founded
- 2016
- Employees
- 160
- Website
- viomelifesciences.com/
- Ownership
- Privately Held (backing)
Viome Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Viome Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Viome Life Sciences in its N-PORT filings yet. We sweep new filings monthly.